Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The U.S. government's principal agency for cancer research
Keytruda plus chemotherapy should be a new standard of care as first-line therapy in patients with esophageal cancer, say researchers.
“Even though the tests have been around for a while, we don’t know how useful they’re really going to be in the clinical setting."
Researchers want to determine whether oligometastatic tumors can either prolong or improve the quality of life for patients.
“It appears that oncologists are not prescribing opioids as much as they did previously."
Adding the targeted drug to chemo and radiation treatment is safe and increases the chance that most of the tumor will die before surgery.
These survivors are more likely to develop high cholesterol, high blood pressure, diabetes, thyroid disorder and other chronic conditions.
A new study has found that a microRNA may help drive the transition from normal fallopian tube cells to cancer in the ovary.
To find a better FTO-targeting drug, researchers searched a collection of 260,000 chemicals housed by NCI.
The gene-editing tool can alter the DNA of human cells like a precise pair of scissors.
"These studies can help researchers develop new strategies to improve the care of women with the worst outcomes for this cancer.”
A greater use of telemedicine has emerged as one of the positive changes that could be continued after the pandemic has passed.
The NCCAPS study will help scientists answer key questions about COVID-19’s impact on cancer patients.
The bottom-line message for breast cancer survivors is “move as often as you can, when you can.”
It was 27% more accurate than the standard approach at detecting any metastases.
“Cancer survivors need the expertise of someone who knows cancer and understands what is ‘normal’ for a cancer survivor.”
The first clinical trial will test a therapy designed to target a protein on cancer cells in young people with acute myeloid leukemia.
This makes a big difference in preventing the more than half a million new cervical cancer cases and over 300,000 deaths globally each year.
“With BAX, we have a single target for blocking both types of cell death stemming from the use of doxorubicin."
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.